HIV and neurocognitive dysfunction

Current HIV/AIDS Reports

Volumn 10, Issue 3, 2013, Pages 235-243

  Spudich, Serena ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute HIV infection; Antiretroviral therapy; Blood brain barrier; Central nervous system; Central nervous system penetration effectiveness; Cerebrospinal fluid; CNS reservoir; Compartmentalization; Efavirenz; HIV escape; HIV reservoir; HIV associated dementia; HIV associated neurocognitive disorder; HIV AIDS; Microglia; Monocyte efficacy; Neurotoxicity; Primary HIV infection; Viral load

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EFAVIRENZ;

ARTICLE; BRAIN NERVE CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CYTOKINE PRODUCTION; ENCEPHALITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PROTON NUCLEAR MAGNETIC RESONANCE; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CENTRAL NERVOUS SYSTEM; COGNITION DISORDERS; HIV INFECTIONS; HUMANS;

EID: 84881474722     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-013-0171-y     Document Type: Article

References (95)

1. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19:517-24. (Pubitemid 16085185)
2. •• Heaton RK, Clifford DB, Franklin Jr DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087-96. This study examined over 1500 persons with chronic HIV infection with detailed neuropsychological testing and identified rates of forms of HAND in the overall cohort as well as in subgroups divded based on nadir CD4, plasma HIV suppression, and presence of comorbidities.
3. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16.
4. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10:317-31. (Pubitemid 38779804)
5. Scott JC, Woods SP, Vigil O, et al. A neuropsychological investigation of multitasking in HIV infection: implications for everyday functioning. Neuropsychology. 2011;25:511-9.
6. Thames AD, Kim MS, Becker BW, et al. Medication and finance management among HIV-infected adults: the impact of age and cognition. J Clin Exp Neuropsychol. 2011;33:200-9.
7. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21:1915-21. (Pubitemid 47329768)
8. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24:1243-50.
9. Centlivre M, Sala M, Wain-Hobson S, Berkhout B. In HIV-1 pathogenesis the die is cast during primary infection. AIDS. 2007;21:1-11. (Pubitemid 44912531)
10. Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol. 2006;18:399-405. (Pubitemid 43947575)
11. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One. 2012;7:e33948.
12. Zink MC, Amedee AM, Mankowski JL, et al. Pathogenesis of SIV encephalitis. Selection and replication of neurovirulent SIV. Am J Pathol. 1997;151:793-803. (Pubitemid 27385611)
13. Lane JH, Sasseville VG, Smith MO, et al. Neuroinvasion by simian immunodeficiency virus coincides with increased numbers of perivascular macrophages/microglia and intrathecal immune activation. J Neurovirol. 1996;2:423-32. (Pubitemid 27011096)
14. Smith MO, Heyes MP, Lackner AA. Early intrathecal events in rhesus macaques (Macaca mulatta) infected with pathogenic or nonpathogenic molecular clones of simian immunodeficiency virus. Lab Invest. 1995;72:547-58.
15. Barber SA, Herbst DS, Bullock BT, et al. Innate immune responses and control of acute simian immunodeficiency virus replication in the central nervous system. J Neurovirol. 2004;10 Suppl 1:15-20. (Pubitemid 38325088)
16. Witwer KW, Gama L, Li M, et al. Coordinated regulation of SIV replication and immune responses in the CNS. PLoS One. 2009;4:e8129.
17. Roberts ES, Burudi EM, Flynn C, et al. Acute SIV infection of the brain leads to upregulation of IL6 and interferon-regulated genes: expression patterns throughout disease progression and impact on neuroAIDS. J Neuroimmunol. 2004;157:81-92. (Pubitemid 39576641)
18. Mankowski JL, Queen SE, Clements JE, Zink MC. Cerebrospinal fluid markers that predict SIV CNS disease. J Neuroimmunol. 2004;157:66-70. (Pubitemid 39576639)
19. Barber SA, Gama L, Dudaronek JM, et al. Mechanism for the establishment of transcriptional HIV latency in the brain in a simian immunodeficiency Virus-Macaque Model. J Infect Dis. 2006;193:963-70.
20. • Zink MC, Brice AK, Kelly KM, et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis. 2010;202:161-70. This study reveals that systemically suppressive ART in an SIV macaque model reduces HIV RNA but does not affect viral DNA in the brain.
21. Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002;16:1119-29. (Pubitemid 34533850)
22. Ho DD, Rota TR, Schooley RT, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med. 1985;313:1493-7. (Pubitemid 16182477)
23. Scarpini E, Sacilotto G, Lazzarin A, et al. Acute ataxia coincident with seroconversion for anti-HIV. J Neurol. 1991;238:356-7.
24. Ben-Galim P, Shaked Y, Vonsover A, Garty M. Immediate immunosuppression caused by acute HIV-1 infection: a fulminant multisystemic disease 2 days post infection. Infection. 1996;24:332-5. (Pubitemid 26273303)
25. Douvoyiannis M, Litman N. Acute encephalopathy and multi-organ involvement with rhabdomyolysis during primary HIV infection. Int J Infect Dis. 2009;13:e299-304.
26. Mogensen TH, Marinovskij E, Larsen CS. Acute demyelinizating encephalomyelitis (ADEM) as initial presentation of primary HIV infection. Scand J Infect Dis. 2007;39:630-4. (Pubitemid 47009181)
27. Calabrese LH, Proffitt MR, Levin KH, et al. Acute infection with the human immunodeficiency virus (HIV) associated with acute brachial neuritis and exanthematous rash. Ann Intern Med. 1987;107:849-51.
28. Serrano P, Hernandez N, Arroyo JA, et al. Bilateral Bell palsy and acute HIV type 1 infection: report of 2 cases and review. Clin Infect Dis. 2007;44:e57-61.
29. Hagberg L, Malmvall BE, Svennerholm L, et al. Guillain-Barre syndrome as an early manifestation of HIV central nervous system infection. Scand J Infect Dis. 1986;18:591-2. (Pubitemid 17197959)
30. Castellanos F, Mallada J, Ricart C, Zabala JA. Ataxic neuropathy associated with human immunodeficiency virus seroconversion. Arch Neurol. 1994;51:236. (Pubitemid 24088405)
31. Denning DW, Anderson J, Rudge P, Smith H. Acute myelopathy associated with primary infection with human immunodeficiency virus. Br Med J (Clin Res Ed). 1987;294:143-4. (Pubitemid 17223862)
32. Taiwo BO, Hicks CB. Primary human immunodeficiency virus. South Med J. 2002;95:1312-7. (Pubitemid 36109342)
33. Stekler J, Collier AC. Primary HIV Infection. Curr HIV/AIDS Rep. 2004;1:68-73.
34. Davis LE, Hjelle BL, Miller VE, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology. 1992;42:1736-9.
35. Tambussi G, Gori A, Capiluppi B, et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis. 2000;30:962-5. (Pubitemid 32250348)
36. Pilcher CD, Shugars DC, Fiscus SA, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS. 2001;15:837-45. (Pubitemid 32424387)
37. Spudich S, Gisslen M, Hagberg L, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis. 2011;204:753-60.
38. • Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206:275-82. This study shows that HIV enters the central nervous system within the first weeks of HIV infection and this viral entry is associated with CNS inflammation.
39. Bell JE, Busuttil A, Ironside JW, et al. Human immunodeficiency virus and the brain: investigation of virus load and neuropathologic changes in pre-AIDS subjects. J Infect Dis. 1993;168:818-24. (Pubitemid 23282552)
40. Anthony IC, Ramage SN, Carnie FW, et al. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol. 2005;64:529-36. (Pubitemid 40781156)
41. McCrossan M, Marsden M, Carnie FW, et al. An immune control model for viral replication in the CNS during presymptomatic HIV infection. Brain. 2006;129:503-16. (Pubitemid 43164372)
42. Gray L, Cowley D, Crespan E, et al. Reduced basal transcriptional activity of central nervous system-derived HIV-1 long terminal repeats. AIDS Res Hum Retroviruses. 2013;29(2):365-70.
43. Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol. 2010;84(5):2395-407.
44. Sonnerborg AB, von Stedingk LV, Hansson LO, Strannegard OO. Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS. 1989;3:277-83. (Pubitemid 19167469)
45. Sailasuta N, Ross W, Ananworanich J, et al. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One. 2012;7:e49272.
46. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5:69-81. (Pubitemid 40070332)
47. Spudich S, Gonzalez-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med. 2012;2:a007120.
48. Lentz MR, Kim WK, Kim H, et al. Alterations in brain metabolism during the first year of HIV infection. J Neurovirol. 2011;17:220-9.
49. Lentz MR, Kim WK, Lee V, et al. Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology. 2009;72:1465-72.
50. Ragin AB, Du H, Ochs R, et al. Structural brain alterations can be detected early in HIV infection. Neurology. 2012;79:2328-34.
51. Wang X, Foryt P, Ochs R, et al. Abnormalities in resting-state functional connectivity in early human immunodeficiency virus infection. Brain Connect. 2011;1:207-17.
52. Ances BM, Sisti D, Vaida F, et al. Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology. 2009;73:702-8.
53. • Peluso MJ, Meyerhoff DJ, Price RW, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary hiv infection. J Infect Dis. 2013;207:1703-12. This analysis found elevated biomarkers of neuronal injury in the CSF in HIV infected subjects within the first year after infection. Biomarkers correlated with CNS inflammation.
54. Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL) - a marker of active HIV-related neurodegeneration. J Neurol. 2007;254:1026-32. (Pubitemid 47353414)
55. Atkinson JH, Higgins JA, Vigil O, et al. Psychiatric context of acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: IV. AIDS Behav. 2009;13:1061-7.
56. Moore DJ, Letendre SL, Morris S, et al. Neurocognitive functioning in acute or early HIV infection. J Neurovirol. 2011;17:50-7.
57. Weber E, Morgan EE, Iudicello JE, et al. Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol. 2013;19:65-74.
58. Eden A, Price RW, Spudich S, et al. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis. 2007;196:1779-83. (Pubitemid 351411938)
59. Yilmaz A, Price RW, Spudich S, et al. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:168-73. (Pubitemid 351172183)
60. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011;25:625-33.
61. Garvey L, Pavese N, Politis M, et al. Microglial cell activation is visualized with [11C]-PK11195 positron emission tomography in neurologically asymptomatic hiv-infected subjects on effective ART. In: 19th Conference for Retroviruses and Opportunistic Infections. Seattle, WA, USA; 2012.
62. Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202:1819-25.
63. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006;66:1447-50.
64. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25:1747-51.
65. Crum-Cianflone NF, Moore DJ, Letendre S, et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology. 2013;80:371-9.
66. Mellgren A, Antinori A, Cinque P, et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther. 2005;10:701-7. (Pubitemid 41376848)
67. Sinclair E, Ronquillo R, Lollo N, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr. 2008;47:544-52. (Pubitemid 351442007)
68. Spudich S, Lollo N, Liegler T, et al. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis. 2006;194:1686-96. (Pubitemid 44901999)
69. d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55:320-8. (Pubitemid 38292033)
70. Letendre S, Ellis RJ, Ances B, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18:45-55.
71. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.
72. Cusini A, Vernazza PL, Yerly S, et al. Higher CNS penetration- effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr. 2013;62:28-35.
73. Garvey L, Winston A, Walsh J, et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology. 2011;76:693-700.
74. Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS. 2011;25:357-65.
75. Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2009;52:56-63.
76. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359-66.
77. Ciccarelli N, Fabbiani M, Colafigli M, et al. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir Ther. 2013;18:153-60.
78. Valcour VG, Shiramizu BT, Sithinamsuwan P, et al. HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology. 2009;72:992-8.
79. Kusao I, Shiramizu B, Liang CY, et al. Cognitive performance related to HIV-1-infected monocytes. J Neuropsychiatr Clin Neurosci. 2012;24:71-80.
80. Shikuma CM, Nakamoto B, Shiramizu B, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther. 2012;17:1233-42.
81. •• Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50:773-8. This is the first description of a series of patients with progressive neurologic disease on stable ART, found to have CSF HIV RNA levels higher than fairly controlled plasma HIV RNA.
82. van Lelyveld SF, Nijhuis M, Baatz F, et al. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid. Clin Infect Dis. 2010;50:387-90.
83. Bogoch II, Davis BT, Venna N. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus. J Infect. 2011;63:236-9.
84. Bingham R, Ahmed N, Rangi P, et al. HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape. Int J STD AIDS. 2011;22:608-9.
85. Tamarit Mdel P, Quereda C, Gonzalez-Rozas M, et al. HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28:83-6.
86. Peluso MJ, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26:1765-74.
87. • Lescure FX, Moulignier A, Savatovsky J, et al. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis. 2013;57:101-8. These authors describe a clinical syndrome of inflammatory encephalitis that may be a form of immune reconstitution inflammatory disease in the CNS.
88. Gray F, Lescure FX, Adle-Biassette H, et al. Encephalitis with Infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment. Brain Pathol. 2013. doi: 10.1111/bpa.12038.
89. Venkataramana A, Pardo CA, McArthur JC, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology. 2006;67:383-8. (Pubitemid 44214957)
90. Cardenas VA, Meyerhoff DJ, Studholme C, et al. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol. 2009;15:324-33.
91. Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010;74:1260-6.
92. Tovar-y-Romo LB, Bumpus NN, Pomerantz D, et al. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther. 2012;343:696-703.
93. Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012;18:388-99.
94. Clifford DB, Evans S, Yang Y, et al. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2009;10:343-55.
95. Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology. 2011;76:1403-9.